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CASE REPORT

Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated
by 18F-FDG PET/CT: a Case Report and Review of Literature
Dominique Fuser1, Matthew L. Hedberg2, Louis P. Dehner2,3, Farrokh Dehdashti1,3, Barry A. Siegel1,3
1

Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO,
USA; 2Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA; 3Alvin J. Siteman
Cancer Center, Washington University School of Medicine, St Louis, MO, USA

Abstract
Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of dedifferentiated renal cell carcinoma. We report a 62-yearold man who presented with respiratory symptoms and a lung mass on chest computed tomography (CT). The patient underwent
positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) and was found to have
extensive metastatic disease. Based on the history and imaging findings, there were possible primary malignancies, including
bronchogenic carcinoma, melanoma, or an aggressive lymphoma. An excisional biopsy surprisingly revealed a high-grade sarcomatoid carcinoma with no evidence of differentiation, and immunohistochemical (IHC) studies showed that the tumor cells
were positive for markers of genitourinary origin (PAX-8 and vimentin). The histologic and IHC results, along with multiple
FDG-avid exophytic lesions in both kidneys, were considered diagnostic of sRCC. Here we have highlighted the potential role of
18
F-FDG-PET-CT in patients with sRCC, discussed the diagnostic challenges, and presented a brief review.
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Introduction
The term “sarcomatoid renal cell carcinoma” (sRCC) was
first used by Farrow et al. in 1968 to describe tumors that had
progressed or transformed to a high grade, pleomorphic often
spindle cell malignancy with a resemblance in most cases
to pleomorphic undifferentiated sarcoma (1). Sarcomatoid

dedifferentiation of a renal cell carcinoma (RCC) can occur
with all histological subtypes. Since clear cell RCC is the most
common subtype, approximately 80–90% of sRCCs are associated with this subtype (2). Sarcomatoid progression may
occur in 10–20% of RCCs in patients with advanced disease
and it is thought to be a major factor in RCC mortality (3, 4).
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Positron emission tomography/computed tomography
(PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) has been
shown to be a valuable tool in the detection of recurrent and
metastatic disease in patients with typical RCC. However,
characterization of the primary tumor can be difficult because
of physiological excretion of FDG by the kidneys. Furthermore, well-differentiated RCCs often have only mildly increased FDG uptake that is similar to that of normal renal
parenchyma (5–8). Since sRCC is more aggressive and has a
higher metastatic potential than conventional RCC, 18F-FDGPET/CT may play an important role in the management and
follow-up of these cases. Review of the literature yielded only
three previously reported cases of metastatic sRCC evaluated by 18F-FDG –PET/CT (9–11). In this report, we describe a case of sRCC in a patient in whom the initial staging
18
F-FDG-PET/CT revealed widespread metastatic disease.

Case Report
A 62-year-old man presented to his primary care physician
with a dry, nonproductive cough with no hemoptysis for

6 weeks. He was initially diagnosed with atypical pneumonia
and started on antibiotics, but his symptoms did not improve.
The patient then presented to the emergency department at
the Washington University Medical Center with worsening
of cough, dyspnea on exertion, left rib pain, weight loss,
and fatigue. A chest radiograph revealed a 9-cm middle mediastinal mass. Further workup with contrast-enhanced CT
disclosed multifocal lesions, including an enhancing right
lower lobe mass invading into the mediastinum, as well as
multiple enhancing soft tissue nodules within the peritoneum, both adrenal glands and the pancreas. These findings
were initially thought to represent a metastatic primary bronchogenic carcinoma.
The patient was referred for 18F-FDG-PET/CT the next
day to further evaluate the disease extent. A whole-body PET/
CT was performed 60 min after the intravenous injection of
629 MBq (17 mCi) 18F-FDG. The study showed multiple hypermetabolic foci throughout the body (Figure 1). There was
a large soft tissue mass in the right lower lobe with increased
18
F-FDG uptake; the maximum standardized uptake value
(SUVmax) of this lesion was 38.0. Also, there were multiple

Figure 1. Maximum intensity projection (MIP) images in anterior and posterior views of the 18F-FDG PET/CT images showing
multiple hypermetabolic foci of increased FDG uptake throughout the body, most likely representing widespread metastatic
disease.
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hypermetabolic nodules in the thyroid, gastric mucosa, pancreas, and both the adrenals. Both kidneys contained exophytic lesions with increased 18F-FDG uptake (Figure 2).
A circumferential soft tissue mass in the esophagus was
hypermetabolic as well. Additional FDG-avid nodules and
masses were also found in the peritoneum and omentum; the
largest of these had a SUVmax of 68.0. Intense FDG uptake
was observed in multiple subcutaneous and intramuscular
nodules throughout the body, some of which were thought
to represent lymph nodes. Brain magnetic resonance imaging
was performed on the same day, which revealed five metastatic lesions measuring up to 1.5 cm in the left frontal lobe,
anterior right parietal lobe, and right temporal lobe. At this
point, there were multiple candidate lesions for the primary
malignancy, such as lung, esophagus, melanoma, or an aggressive lymphoma.
An excisional biopsy of the right cervical lymph node
was performed based on the 18F-FDG PET/CT findings. A
portion of this tissue was sent for flow cytometry prior to
microscopic analysis, to exclude a hematologic malignancy,
and a standard lymphoma analysis was performed. Front
and side scatter size gating found 0% of the cells to be blasts,
and only 2% of the cells were identified as lymphocytes. Of
these gated cells (lymphocytes), 0% were positive for the pan
B-cell markers CD-19 and CD-20. Furthermore, no clonality assessed by kappa/lambda staining was identified. Of
the gated cells, 95% were positive for the pan T-cell marker
CD-3. This was consistent with entire replacement of the
lymph node with tumor. The rare hematologic cells that
were identified represented a small population of tumor infiltrating T-cells, a common phenomenon. The remaining
portion was sent for histologic analysis, and was found to
be a high-grade sarcomatoid carcinoma with no evidence of

differentiation (Figure 3A). Immunostaining demonstrated
the tumor cells were negative for both cytokeratin 7 and 20,
and positive for vimentin and PAX-8, suggesting that the
cancer in the sampled cervical lymph node was most likely
a metastasis from a primary cancer of genitourinary origin.
After correlation with the imaging studies, which identified
bilateral, FDG-avid, exophytic lesions in the kidneys, a final
diagnosis of sarcomatoid carcinoma of renal origin was
rendered (Figure 3B). A detailed listing of the reagents used
for histopathologic analysis of the tumor tissue is available
on the journal’s website at: https://jkcvhl.com/index.php/
jkcvhl/rt/suppFiles/99/0.
The patient underwent stereotactic radiosurgery to five
brain lesions, and chemotherapy with carboplatin and paclitaxel protein-bound particles (ABRAXANE®) was immediately initiated. He did not tolerate the treatment well and
CT showed progression of the disease. Second-line treatment
with pembrolizumab was started. Unfortunately, a few days
after the first cycle, the patient died.

Discussion
sRCC is a highly malignant tumor that contains features
similar to sarcomas, with spindle-like cells, high cellularity,
and cellular atypia (4). Patients with sRCC have the worst
prognosis among all patients with RCC, even among those
with initially localized disease, with a median overall survival
of 3 to 10 months (12). Preclinical and clinical data suggest
susceptibility to cytotoxic agents and vascular endothelial
growth factor-targeted therapies, but with poor response
rates (13). A study by Joseph et al. has shown that sRCCs
express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, making sRCC patients good

Figure 2. Axial 18F-FDG PET/CT fusion images. Foci of markedly increased 18F-FDG uptake are shown in the peritoneal cavity,
and in exophytic lesions in the kidneys bilaterally.
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Figure 3. A diagnostic challenge. (A) On hematoxylin–eosin staining, this excisional biopsy demonstrates a lymph node that has
been entirely replaced by a high-grade, eosinophilic, homogeneously sarcomatoid malignancy with no evidence of differentiation. There is a high degree of both cellular atypia, ranging from spindled cells to fried egg cells, and nuclear atypia, featuring vesicular chromatin, irregular nuclear borders, and prominent nucleoli. A portion of this tissue was sent for flow cytometry
prior to microscopic analysis, which excluded a hematologic malignancy, as no significant lymphoid population was identified.
(B) Immunostaining to identify the tissue of origin for this malignancy demonstrated tumor cell nonreactivity for cytokeratins
7 and 20, with reactivity for vimentin and PAX8. These immunohistochemical and morphological findings are most consistent with
a high-grade sarcomatoid carcinoma of renal origin. (C) Interrogation of prognostic/predictive markers by immunohistochemistry
demonstrated high PD-L1 expression levels and was negative for BRAF V600E hotspot mutation. Fluorescence In Situ Hybridization studies with break-apart probes were negative for rearrangements in ALK and ROS1, suggesting that this patient might benefit
from treatment with pembrolizumab and would be less likely to benefit from treatment with crizotinib and dabrafenib.

candidates for treatment with anti–PD-1/PD-L1 agents (14).
Phase 1 data with atezolizumab, a PD-L1 antibody, showed
early evidence of antitumor activity in sRCC, with an
objective response rate of 22% (15). However, further studies are needed to establish the optimal combination of cytotoxic chemotherapy, targeted agents, and immunotherapy to
improve outcomes in these patients.
The role of 18F-FDG-PET/CT for primary RCC is still
controversial because of the renal excretion of 18F-FDG and
the relatively low 18F-FDG uptake of many tumors (8). However, 18F-FDG PET/CT has shown to be effective for detection of suspected recurrent RCC (5, 8).
The use of 18F-FDG-PET/CT in the evaluation of sRCC
has only been described in three prior case reports. Thambugala et al. described metastatic dissemination of a sRCC
after nephrectomy (9). Conventional imaging of this patient
with recurrent sRCC showed metastatic spread to para-aortic

nodes, but 18F-FDG-PET/CT identified extensive local
recurrence that involved the left renal bed and retroperitoneal soft tissues, as well as abdominal and mediastinal nodal
and 
osseous metastases. Hyodo et al. reported a patient
with sRCC in whom post-nephrectomy 18F-FDG-PET/CT
demonstrated disseminated metastatic lesions in mediastinal
lymph nodes, lungs, and the right infraspinatus muscle with
intense 18F-FDG uptake (10).
Recently, Nadebaum et al. also reported a patient with
recurrent sRCC, who had two subpopulations of disease with
different imaging phenotypes on PET/CT with 18F-FDG
and with the prostate-specific membrane antigen (PSMA)
ligand, 68Ga-PSMA-HBED-CC. Based on the findings in
this patient, they suggested that the sarcomatoid dedifferentiation is associated with a loss of PSMA expression and a
concomitant upregulation of GLUT-1 transporter expression, increasing 18F-FDG avidity (11).
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In all three prior reports, 18F-FDG-PET/CT was performed after nephrectomy to evaluate recurrent/metastatic
disease and, therefore, evaluation of primary sRCC was not
possible. Our patient had metastatic disease of unknown primary origin at the time of the PET/CT study. After the final
diagnosis of sRCC, the renal lesions were recognized retrospectively as multiple hypermetabolic exophytic lesions bilaterally, with high 18F-FDG uptake relative to that of normal
renal parenchyma. The findings in our patient also demonstrate the high 18F-FDG avidity of sRCC metastatic lesions,
consistent with the findings of the three previously reported
cases.
Histologically, this was a very high-grade lesion. The
primitive phenotype of the cancer cells posed a diagnostic challenge in the setting of widespread disease
and significant tumor burden in multiple organs, any of
which could have been the primary tumor site. While the
initial panel of immunostains suggested the primary
lesion to be of urogenital origin, it also revealed a significant and unanticipated result, as portions of the tumor
demonstrated positivity for SOX10, which is expressed
predominantly in melanocytes, Schwann cells, and breast
myoepithelial cells (16). Clinically, it is considered to be
a relatively specific marker of melanomas, but it is also
known to be positive in some malignant peripheral nerve
sheath tumors as well as in some basal-like, triple-negative
breast cancers, especially those with a metaplastic carcinoma component (17). Additional assessment of this lesion
by MiTF and tyrosinase staining, both of which were negative, further supported that this tumor was not a melanoma.
Rather, the tumor was most likely an sRCC aberrantly expressing primitive transcription factors known developmentally to be crucial in the specification of neural crest cells
(16). To our knowledge, this is the first reported case of a
SOX10-positive sRCC.
Given the unique cellular and molecular phenotypes observed in the excisional biopsy, it would have been interesting to sample additional lesions from this patient in order to
assess whether or not a gradient of dedifferentiation and/or
epithelial to mesenchymal transition exists between the primary tumors and the various deposits of metastatic disease,
which demonstrated significant variation in the SUVmax on
18
F-FDG-PET/CT.

Conclusion
sRCC is a highly aggressive malignancy reported in some
instances to overexpress GLUT-1 transporters, potentially
resulting in high 18F-FDG avidity. Although the impact of
18
F-FDG-PET/CT in sRCC has only been reported in three
cases of recurrent disease, and must be further evaluated, the
findings in our patient suggest that 18F-FDG-PET/CT is also
potentially valuable for the evaluation of primary sRCC and
initial staging for detection of metastatic lesions.
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